CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2026)
CG Oncology filings provide 3 years of Depreciation & Amortization (CF) readings, the most recent being $849000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) changed N/A to $849000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 4415.62% increase, with the full-year FY2025 number at $1.4 million, up 4415.62% from a year prior.
- Depreciation & Amortization (CF) hit $849000.0 in Q4 2025 for CG Oncology, up from $416000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $849000.0 in Q4 2025 to a low of $4000.0 in Q1 2023.
- Median Depreciation & Amortization (CF) over the past 3 years was $7000.0 (2024), compared with a mean of $135818.2.
- Biggest five-year swings in Depreciation & Amortization (CF): changed 0.0% in 2024 and later skyrocketed 2128.57% in 2025.
- CG Oncology's Depreciation & Amortization (CF) stood at $4000.0 in 2023, then skyrocketed by 425.0% to $21000.0 in 2024, then surged by 3942.86% to $849000.0 in 2025.
- The last three reported values for Depreciation & Amortization (CF) were $849000.0 (Q4 2025), $416000.0 (Q3 2025), and $156000.0 (Q2 2025) per Business Quant data.